Current management of onychomycosis. An overview

• Published in: Dermatologic clinics Vol. 15; no. 1; p. 121
• Main Authors: Gupta, A K, Scher, R K, De Doncker, P
• Format: Journal Article
• Language: English
• Published: United States 01-01-1997
• Subjects: Antifungal Agents - administration & dosage; Antifungal Agents - therapeutic use; Clinical Trials as Topic; Evaluation Studies as Topic; Foot Dermatoses; Hand Dermatoses; Humans; Onychomycosis - drug therapy; Onychomycosis - etiology; Onychomycosis - physiopathology
• ISSN: 0733-8635
• DOI: 10.1016/S0733-8635(05)70420-4

Until recently pedal onychomycosis, particularly when it affected several nails or involved a large nail plate area, was often regarded as untreatable. The advent of new therapies such as itraconazole, terbinafine, and fluconazole has been a significant and welcome addition to the armamentarium of therapies at the disposal of the physician. These drugs appear in the nail plate within days of starting oral therapy, being taken up by both the nail matrix and the nail bed. The duration required for effective therapy has been reduced, while the efficacy rates and cost-effectiveness have increased compared with the older treatments, such as griseofulvin. Some of the newer agents appear to have a wider spectrum of activity. Thus far, the newer agent have exhibited a low risk to benefit ratio. I may be possible to combine oral therapies with topical and surgical treatments, thereby further increasing efficacy rates and the cost-effectiveness while decreasing adverse effects and duration of oral therapy.